share_log

南新制药(688189.SH)业绩快报:2023年度净利润354.77万元 同比扭亏

Nanxin Pharmaceutical (688189.SH) Performance Report: 2023 net profit of 3,547,700 yuan reverses year-on-year losses

Gelonghui Finance ·  Feb 28 20:54

Gelonghui, Feb. 28, 丨 Nanxin Pharmaceutical (688189.SH) announced its 2023 annual performance report. During the reporting period, the company achieved operating income of 744 million yuan, an increase of 6.50% over the same period of the previous year; achieved operating profit of 7.5947 million yuan, achieved a total profit of 6.9344 million yuan, and realized net profit attributable to shareholders of listed companies of 3,5477 million yuan, turning a loss into a profit over the previous year. As of December 31, 2023, the company's total assets were 1725.9855 million yuan, a decrease of 11.66% over the same period of the previous year; owners' equity attributable to the parent company was 1317.912,200 yuan, an increase of 0.27% over the same period of the previous year; and the net assets per share attributable to the owners of the parent company were 4.80 yuan, a decrease of 28.46% over the same period last year.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment